Market Scenario:
Carcinoid tumor is a type of the neuroendocrine tumor. A neuroendocrine tumor develops in the body’s neuroendocrine system, which is made up of cells that are a combination of hormone-producing endocrine cells and nerve cells. The most common site of carcinoid tumors is GI (gastrointestinal) tract and lungs. The other sites for the development of the carcinoid tumors is inclusive of the pancreas, testicles, and ovaries. According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract. Moreover, it was also estimated that each year approximately 4,000 adults in the United States diagnose with the carcinoid tumor in their lung. Thus, the prevalence of the carcinoid tumor is expected to drive the market. In 2016, American Society of Clinical Oncology (ASCO) published a report stating that the people who were diagnosed with carcinoid tumor were in their early 60s. Additionally, according to the report of WHO published in 2015, the geriatric population is expected to double and reach 2.1 billion by 2050. Thus, the growing geriatric population along with rising healthcare expenditure is set to boost the market growth during the forecast period. However, lack of awareness, treatment cost and related side effects may restrain the market growth during the forecast period.
Carcinoid tumor is a type of the neuroendocrine tumor. A neuroendocrine tumor develops in the body’s neuroendocrine system, which is made up of cells that are a combination of hormone-producing endocrine cells and nerve cells. The most common site of carcinoid tumors is GI (gastrointestinal) tract and lungs. The other sites for the development of the carcinoid tumors is inclusive of the pancreas, testicles, and ovaries. According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract. Moreover, it was also estimated that each year approximately 4,000 adults in the United States diagnose with the carcinoid tumor in their lung. Thus, the prevalence of the carcinoid tumor is expected to drive the market. In 2016, American Society of Clinical Oncology (ASCO) published a report stating that the people who were diagnosed with carcinoid tumor were in their early 60s. Additionally, according to the report of WHO published in 2015, the geriatric population is expected to double and reach 2.1 billion by 2050. Thus, the growing geriatric population along with rising healthcare expenditure is set to boost the market growth during the forecast period. However, lack of awareness, treatment cost and related side effects may restrain the market growth during the forecast period.
The global carcinoid tumor market is expected to
grow at an approximate of CAGR of 10.5% during forecast period.
Key Players
·
Novartis
AG (Europe)
·
Amgen
Inc. (U.S.)
·
Boehringer
Ingelheim GmbH (Europe)
·
AVEO
Pharmaceuticals, Inc. (U.S.)
·
Chiasma,
Inc. (U.S.)
·
Aegis
Therapeutics, LLC (U.S.)
·
CRINETICS
PHARMACEUTICALS (U.S.)
·
Delcath
Systems Inc. (U.S.)
·
Exelixis,
Inc. (U.S.)
Regional Analysis
America dominates the global
carcinoid tumor market owing to a well-developed healthcare sector and huge
patient population. Apart from this, increasing healthcare expenditure and
presence of developed economies within the region are adding fuel to the growth
of the market in America.
Europe is the second leading
region in the global carcinoid tumor market, which is followed by Asia Pacific.
Availability of funds for research, huge patient population and government
support for research & development are projected to drive the market. According
to the National Health Service in 2015, each year about 1,200 people diagnose
with carcinoid tumor in the UK.
Asia Pacific is the fastest
growing region in the market due to the presence of a huge patient population,
continuously developing economies like India and China, and the presence of
huge opportunity in the market. Moreover, there are huge opportunities within
the region for the growth of the untapped market.
On the other hand, the Middle
East & Africa accounts the least share of the global carcinoid tumor market
due to presence of poor economy, especially, in Africa region. Majority of the
market of this region is held by the Middle East due to a well-developed
healthcare sector and huge healthcare expenditure.
Segmentation
The global carcinoid tumor market
is segmented on the basis of site, diagnosis, treatment, and end users.
On the basis of site, the market
is segmented into gastrointestinal, lung, and others. Furthermore, the
gastrointestinal segment is sub-segmented into rectum, small intestine,
appendix, and others. The lung segmented is sub-segmented into typical,
atypical, and others.
On the basis of diagnosis, the
market is segmented into serology, imaging, biopsy, and others. The serology
segment is sub-segmented into blood test, urine test, molecular test, and
others. The imaging segment is sub-segmented into X-ray, CT scan, PET scan, and
others.
On the basis of treatment, the
market is segmented into surgery, chemotherapy, radiotherapy, and others. The
surgery segment is sub-segmented into local excision, radiofrequency ablation
(RFA), and others.
On the basis of end users, the
market is segmented into hospitals & clinics, academic institutes, research
organization, and others.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1
Definition
2.2
Scope Of The Study
2.2.1
Research Objective
2.2.2 Assumptions
2.2.3
Limitations
Chapter 3. Research Methodology
3.1
Introduction
3.2
Primary Research
3.3
Secondary Research
3.4
Market Size Estimation
Chapter 4. Market Dynamics
4.1
Drivers
4.2
Restrains
4.3
Opportunities
4.4
Challenges
4.5
Macroeconomic Indicators
4.6
Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1
Porters Five Forces Analysis
5.1.1
Bargaining Power Of Suppliers
5.1.2
Bargaining Power Of Buyers
5.1.3
Threat Of New Entrants
5.1.4
Threat Of Substitutes
5.1.5
Intensity Of Rivalry
About US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact
Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com